Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes

Diabetes Care

Volumn 38, Issue 1, 2015, Pages 132-139

  Lovshin, Julie A ^a   Barnie, Annette ^b   DeAlmeida, Ariana ^b   Logan, Alexander ^a   Zinman, Bernard ^a,b   Drucker, Daniel J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; HEMOGLOBIN A1C; LIRAGLUTIDE; PLACEBO; BRAIN NATRIURETIC PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); SODIUM;

ADULT; APPETITE DISORDER; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CANADA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DYSPEPSIA; FEMALE; FLATULENCE; HEART RATE; HUMAN; HYPERTENSION; MALE; NATRIURESIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; AGED; AGONISTS; ANALOGS AND DERIVATIVES; BIOASSAY; BLOOD; BLOOD PRESSURE; CROSSOVER PROCEDURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; URINE;

ADULT; AGED; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; BODY WEIGHT; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURESIS; NATRIURETIC PEPTIDE, BRAIN; OBESITY; PEPTIDE FRAGMENTS; RECEPTORS, GLUCAGON; SODIUM;

EID: 84920053430     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1958     Document Type: Article

References (23)

1. Seshasai SR, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of causespecific death. N Engl J Med 2011;364:829-841
2. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies [published correction appears in Lancet 2010;376:958]. Lancet 2010; 375:2215-2222
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
5. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014;8:330-339
6. Ussher JR, Baggio LL, Campbell JE, et al. Inactivation of the cardiomyocyte glucagonlike peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metab 2014;3:507-517
7. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 2014;114: 1788-1803
8. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004;89: 3055-3061
9. Skov J, Dejgaard A, Frøkiær J, et al. Glucagon-like peptide-1 (GLP-1): Effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 2013;98: E664-E671
10. Gutzwiller JP, Hruz P, HuberAR, et al.Glucagonlike peptide-1 is involved in sodium and water homeostasis in humans. Digestion 2006;73:142-150
11. Skov J, Holst JJ, Gotze JP, Frokiaer J, Christiansen JS. Glucagon-like peptide-1: Effect on pro-atrial natriuretic peptide in healthy males. Endocr Connect 2014;3:11-16
12. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013;19:567-575
13. Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications 2014;28:399-405
14. Li CJ, Yu Q, Yu P, et al. Changes in liraglutideinduced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc Diabetol 2014;13:36
15. Padmanabhan S, Newton-Cheh C, Dominiczak AF. Genetic basis of blood pressure and hypertension. Trends Genet 2012;28:397-408
16. Bertoni AG, Wagenknecht LE, Kitzman DW, Marcovina SM, Rushing JT, Espeland MA; Brain Natriuretic Peptide Subgroup of the Look AHEAD Research Group. Impact of the Look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity (Silver Spring) 2012;20:1511-1518
17. Chainani-Wu N, Weidner G, Purnell DM, et al. Relation of B-type natriuretic peptide levels to body mass index after comprehensive lifestyle changes. Am J Cardiol 2010;105: 1570-1576
18. Chen-Tournoux A, Khan AM, Baggish AL, et al. Effect of weight loss after weight loss surgery on plasma N-terminal pro-B-type natriuretic peptide levels. Am J Cardiol 2010;106: 1450-1455
19. Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A doubleblind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010;9:6
20. Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide- 1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 2014;64: 731-737
21. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide- 1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32:1224-1230
22. Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-1610
23. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia 2009; 52:2046-2055